Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001628280-25-040442
Filing Date
2025-08-14
Accepted
2025-08-14 20:31:31
Documents
4
Period of Report
2025-08-12

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1755217885.html 3  
1 FORM 3 wk-form3_1755217885.xml 3 1708
2 EX-24 ex24poakirske.htm EX-24 8166
3 image_0.jpg GRAPHIC 11612
4 image_1.jpg GRAPHIC 125
  Complete submission text file 0001628280-25-040442.txt   27436
Mailing Address C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET, 4TH FLOOR BOSTON MA 02134
Business Address
KIRSKE DAVID (Reporting) CIK: 0001276750 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38295 | Film No.: 251222038

Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Issuer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)